HPV vaccination

Overview

Human papillomavirus (HPV) vaccination is a preventive immunotherapy strategy designed to protect against infection by oncogenic strains of human papilloma virus, a sexually transmitted pathogen responsible for the majority of cervical cancers, as well as oropharyngeal, anal, vulvar, vaginal, and penile malignancies. Currently licensed vaccines — including the bivalent, quadrivalent, and nonavalent formulations — elicit robust humoral immune responses targeting the L1 capsid proteins of high-risk HPV (hrHPV) genotypes, most critically HPV-16 and HPV-18, which together account for approximately 70% of cervical cancer cases. By generating high-titer neutralizing antibodies prior to initial exposure, vaccination prevents viral integration into host epithelial cell DNA, thereby interrupting the carcinogenic cascade that — through mechanisms including oncogene-driven cellular senescence bypass — ultimately leads to recurrent cervical cancer and other HPV-associated malignancies.

Vaccination programs are generally recommended for adolescents before sexual debut, though catch-up schedules extend eligibility into early adulthood. Despite decades of safety and efficacy data, global uptake remains heterogeneous, shaped by healthcare infrastructure, socioeconomic factors, cultural attitudes, and policy environments. Population-level evidence from organized cervical screening programs has increasingly demonstrated real-world reductions in hrHPV prevalence and precancerous lesions among vaccinated cohorts, underscoring the public health imperative of achieving high and equitable coverage.

Focus of Latest Publications

Recent literature has concentrated heavily on two intersecting themes: documenting the measurable population-level impact of HPV vaccination programs and identifying persistent barriers to optimal uptake across diverse populations and settings.

Population-level effectiveness has been rigorously assessed in organized screening contexts. A population-based study evaluating three Italian areas covered by organized cervical screening reported first estimates of HPV vaccination impact among women who had been invited for vaccination at ages 15–16 and subsequently reached cervical screening age at 25 years beginning in 2018 (PMID: 42084786). This cohort-linked design allowed direct comparison of hrHPV infection rates and lesion burden between vaccinated and unvaccinated women entering screening, providing among the earliest Italian real-world effectiveness data. Similarly, a study utilizing the US National Health and Nutrition Examination Survey (NHANES) examined population-level prevalence and risk of oral HPV infection, confirming that although HPV vaccination is effective at reducing infection burden, uptake remains suboptimal and disparities persist across demographic groups (PMID: 42080318).

Uptake disparities and structural barriers have emerged as a dominant research concern. An analysis of 2023 National Immunization Survey-Teen data investigated whether state minor consent laws — policies allowing adolescents to consent to vaccination without parental authorization — were associated with increased HPV vaccination rates, ultimately finding no significant association in either unadjusted or multivariate logistic regression models (PMID: 42019130). This finding challenges a commonly proposed policy lever for improving adolescent vaccination coverage. In Morocco, a national cross-sectional study measured the prevalence of HPV vaccination hesitancy among young girls, identifying challenges rooted in HPV knowledge gaps, vaccine safety beliefs, and socio-cultural factors (PMID: 42160355).

Targeted high-risk populations have received specific attention. A quality improvement study focused on patients undergoing loop electrosurgical excision procedure (LEEP) at colposcopy — a cohort at elevated risk for recurrent cervical cancer due to prior high-grade lesions — sought to increase HPV vaccination rates by 15% over six months through structured clinical intervention (PMID: 41825633). The colposcopy clinic setting was identified as an underutilized opportunity to reach individuals who have already experienced HPV-related disease. A parallel study examining women presenting for abortion similarly identified HPV vaccination and cervical screening uptake as interconnected prevention opportunities, noting that clinical encounters for sexual and reproductive health services represent natural touchpoints for vaccination (PMID: 41224642).

Healthcare workers represent another under-examined high-risk group. Research on occupational HPV exposure among healthcare workers found that despite meaningful professional exposure risk, HPV vaccination uptake in this population remains suboptimal, with findings carrying direct implications for institutional vaccination strategies (PMID: 42189578).

Educational interventions have been explored as a demand-side strategy. A French pilot observational study assessed the association between a school-based educational intervention and parental acceptance and HPV vaccination uptake within a national campaign, illustrating how structured educational programs delivered in school settings may influence parental attitudes and vaccination behavior (PMID: 42044612).

Key Publications

• May Occupational HPV exposure and vaccination among healthcare workers: Implications for institutional vaccination strategies. (Human vaccines & immunotherapeutics, 2026, PMID 42189578): "Despite this exposure, HPV vaccination uptake among healthcare workers remains suboptimal."
• May State minor consent laws and human papilloma virus vaccine uptake: An analysis of the 2023 National Immunization Survey-Teen Data. (Vaccine, 2026, PMID 42019130): "In both models, our results indicate that state minor consent laws are not associated with increased HPV vaccination."
• May Association a school-based educational program and human papillomavirus (HPV) vaccination uptake in France: A pilot observational study. (Vaccine, 2026, PMID 42044612): "This study aimed to assess the association between a school-based educational intervention and parental acceptance and HPV vaccination uptake within the national campaign."
• May Challenges to human papillomavirus vaccination among young girls in Morocco: A national cross-sectional study. (PloS one, 2026, PMID 42160355): "our study aimed to measure the prevalence of HPV vaccination hesitancy among young girls"
• May Population-Based First Estimates of the Effect of HPV Vaccination in Three Italian Areas Covered by Organised Cervical Screening. (International journal of cancer, 2026, PMID 42084786): "In Italy, the first women invited for HPV vaccination at 15-16 years reached the age for cervical screening (25 years) in 2018."
• May Population-level prevalence and risk of oral HPV infection with or without HPV vaccination. (Human vaccines & immunotherapeutics, 2026, PMID 42080318): "Although HPV vaccination is effective, uptake remains suboptimal and disparities persist."
• May Enhancing Human Papillomavirus Vaccination Uptake After Loop Electrosurgical Excision Procedure (LEEP) at Colposcopy: A Quality Improvement Study. (Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2026, PMID 41825633): "Our primary objective aimed to increase the HPV vaccination rate by 15% over 6 months among a high-risk patient population seen in colposcopy."
• Apr Human papillomavirus vaccination and cervical screening uptake among women presenting for abortion: exploring opportunities for health care interventions. (BMJ sexual & reproductive health, 2026, PMID 41224642): "Prevention efforts rely on vaccination and cervical screening."